These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12387040)

  • 21. [Short acting insulin analogues for treating diabetic patients with CSII (continuous subcutaneous insulin infusion)].
    Jermendy G
    Orv Hetil; 2006 Nov; 147(46):2223-6. PubMed ID: 17396394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).
    Hirao K; Arai K; Yamauchi M; Takagi H; Kobayashi M;
    Diabetes Res Clin Pract; 2008 Jan; 79(1):171-6. PubMed ID: 17919762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Supplemental insulin therapy of type 2 diabetes follows the example of nature. Replace what the patient lacks].
    MMW Fortschr Med; 2004 May; 146(22):47. PubMed ID: 15373112
    [No Abstract]   [Full Text] [Related]  

  • 24. [Flexibility and effectiveness of diabetes therapy].
    Krankenpfl J; 2005; 43(1-3):62. PubMed ID: 15912849
    [No Abstract]   [Full Text] [Related]  

  • 25. Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus.
    Velásquez-Mieyer PA; Neira CP
    Expert Opin Pharmacother; 2008 Sep; 9(13):2377-82. PubMed ID: 18710361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous subcutaneous insulin infusion--an historical perspective.
    Skyler JS
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S5-9. PubMed ID: 20515307
    [No Abstract]   [Full Text] [Related]  

  • 27. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.
    Cengiz E; Weinzimer SA; Sherr JL; Tichy EM; Carria L; Cappiello D; Steffen A; Tamborlane WV
    Diabetes Technol Ther; 2014 Jan; 16(1):20-5. PubMed ID: 24367934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
    Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
    Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemoglobin A1c values and CGM.
    Blevins T
    Diabetes Technol Ther; 2012 Oct; 14(10):971; author reply 972. PubMed ID: 23013204
    [No Abstract]   [Full Text] [Related]  

  • 30. Benefits of combination therapy of insulin and oral hypoglycemic agents.
    Garber AJ
    Arch Intern Med; 2003 Aug 11-25; 163(15):1781-2. PubMed ID: 12912710
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump.
    Chlup R; Zapletalová J; Seckar P; Chlupová L; Táncosová S; Reznícková M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):27-32. PubMed ID: 15523542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes.
    Tamemoto H; Ikoma A; Saitoh T; Ishikawa SE; Kawakami M
    Diabetes Technol Ther; 2007 Jun; 9(3):246-53. PubMed ID: 17561795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in treating diabetes with aerosolized insulin.
    Laube BL
    Diabetes Technol Ther; 2002; 4(4):515-8. PubMed ID: 12396746
    [No Abstract]   [Full Text] [Related]  

  • 35. [From human insulin to designer insulin. Why insulin analogs?].
    Jungmann E
    Fortschr Med; 1997 Apr; 115(12):40-1. PubMed ID: 9235302
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B; Weinstein R; Bell D; McGill J; Nadeau D; Raskin P; Davidson J; Henry R; Huang WC; Reinhardt RR
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A closed-loop artificial pancreas using model predictive control and a sliding meal size estimator.
    Lee H; Buckingham BA; Wilson DM; Bequette BW
    J Diabetes Sci Technol; 2009 Sep; 3(5):1082-90. PubMed ID: 20144421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 39. HONE IN ON THE RANGE.
    Scheiner G
    Diabetes Self Manag; 2015; 32(4):18-20, 23. PubMed ID: 26380396
    [No Abstract]   [Full Text] [Related]  

  • 40. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
    MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.